http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 18:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Krystal+Biotech%2C+Inc.+++++For%3A+Aug+14++Filed+by%3A+ROSSI+DINO+A/26933125.html si-local-file:///var/storage/secattach/20260814/26933125.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Krystal+Biotech%2C+Inc.+++++For%3A+Aug+14++Filed+by%3A+ROSSI+DINO+A/26933125.html Fri, 14 Aug 2026 18:23:00 -0400 KRYS O.34832706 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Krystal+Biotech%2C+Inc.+++++For%3A+Aug+14++Filed+by%3A+ROSSI+DINO+A/26933125.html si-local-file:///var/storage/secattach/20260814/26933125.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Krystal+Biotech%2C+Inc.+++++For%3A+Aug+14++Filed+by%3A+ROSSI+DINO+A/26933125.html Fri, 14 Aug 2026 18:23:00 -0400 KRYS O.34832706 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Krystal+Biotech%2C+Inc.++++++++++++++++++Filed+by%3A+ROSSI+DINO+A/26932828.html si-local-file:///var/storage/secattach/20260814/26932828.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Krystal+Biotech%2C+Inc.++++++++++++++++++Filed+by%3A+ROSSI+DINO+A/26932828.html Fri, 14 Aug 2026 17:22:00 -0400 KRYS O.34832706 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Krystal+Biotech%2C+Inc.++++++++++++++++++Filed+by%3A+ROSSI+DINO+A/26932828.html si-local-file:///var/storage/secattach/20260814/26932828.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Krystal+Biotech%2C+Inc.++++++++++++++++++Filed+by%3A+ROSSI+DINO+A/26932828.html Fri, 14 Aug 2026 17:22:00 -0400 KRYS O.34832706 http://www.streetinsider.com/New+Coverage/RBC+Capital+Starts+Krystal+Biotech+%28KRYS%29+at+Outperform/26923600.html <p>RBC Capital initiates coverage on Krystal Biotech (NASDAQ: KRYS) with a Outperform rating and a price target of $400.00.</p><p>For an analyst ratings summary and ratings history on Krystal Biotech <a href="http://www.streetinsider.com/rating_history.php?q=KRYS">click here</a>. For more ratings news on Krystal Biotech <a href="http://www.streetinsider.com/stock_lookup_news.php?q=KRYS&amp;type=analyst">click here</a>.</p><p>Shares of Krystal Biotech closed at $328.34 yesterday.</p> http://www.streetinsider.com/New+Coverage/RBC+Capital+Starts+Krystal+Biotech+%28KRYS%29+at+Outperform/26923600.html Fri, 14 Aug 2026 05:28:07 -0400 KRYS http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%26apos%3Bs+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905237.html <p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1&apos;s success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%26apos%3Bs+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905237.html Tue, 11 Aug 2026 15:35:00 -0400 A.17150087 A.42844528 A.50210626 AXGN CNXU KRYS NVST O.00092737 O.00644714 O.13287785 O.23744242 O.34832706 O.34929518 O.41906525 VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%26apos%3Bs+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905237.html <p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1&apos;s success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%26apos%3Bs+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905237.html Tue, 11 Aug 2026 15:35:00 -0400 A.17150087 A.42844528 A.50210626 AXGN CNXU KRYS NVST O.00092737 O.00644714 O.13287785 O.23744242 O.34832706 O.34929518 O.41906525 VCEL